Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8670142 | 1.00 | CA2 (0.52) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL11477145 | 1.00 | CA2 (0.52) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL11458588 | 1.00 | CA2 (0.52) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL11477827 | 1.00 | CA2 (0.52) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL11475280 | 0.98 | CA2 (0.53) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL15401578 | 0.96 | MAPT (0.48) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL8356601 | 0.94 | MAPT (0.52) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL11459440 | 0.92 | CA2 (0.55) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL2994424 | 0.90 | KMT2A (0.54) | TSHRTDP1MAPTKMT2AALDH1A1 | |
| SCHEMBL9957518 | 0.90 | KMT2A (0.61) | TSHRTDP1MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4240983-A | HALOGENATION | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-23 | — | — | US | claimed |
| EP-2397475-B1 | 4, 4' disubstituted 4H-cyclopentadithiophene and new methods for synthesising the same | IMEC (BE) | 2014-11-12 | — | — | EP | disclosed |
| EP-2397475-B1 | 4, 4' disubstituted 4H-cyclopentadithiophene and new methods for synthesising the same | IMEC (BE) | 2014-11-12 | — | — | EP | disclosed |
| US-8329923-B2 | 4, 4′ disubstituted 4H-cyclopentadithiophene and new methods for synthesizing the same | IMEC (BE) | 2012-12-11 | — | — | US | disclosed |
| US-8329923-B2 | 4, 4′ disubstituted 4H-cyclopentadithiophene and new methods for synthesizing the same | IMEC (BE) | 2012-12-11 | — | — | US | disclosed |
| US-8329923-B2 | 4, 4′ disubstituted 4H-cyclopentadithiophene and new methods for synthesizing the same | IMEC (BE) | 2012-12-11 | — | — | US | disclosed |
| US-20110313175-A1 | 4, 4' DISUBSTITUTED 4H-CYCLOPENTADITHIOPHENE AND NEW METHODS FOR SYNTHESISING THE SAME | UNIVERSITEIT HASSELT (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110313175-A1 | 4, 4' DISUBSTITUTED 4H-CYCLOPENTADITHIOPHENE AND NEW METHODS FOR SYNTHESISING THE SAME | UNIVERSITEIT HASSELT (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110313175-A1 | 4, 4' DISUBSTITUTED 4H-CYCLOPENTADITHIOPHENE AND NEW METHODS FOR SYNTHESISING THE SAME | UNIVERSITEIT HASSELT (BE) | 2011-12-22 | — | — | US | disclosed |
| EP-2397475-A1 | 4, 4' disubstituted 4H-cyclopentadithiophene and new methods for synthesising the same | IMEC (BE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397475-A1 | 4, 4' disubstituted 4H-cyclopentadithiophene and new methods for synthesising the same | IMEC (BE) | 2011-12-21 | — | — | EP | disclosed |
| US-4240983-A | HALOGENATION | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313175-A1 | 4, 4' DISUBSTITUTED 4H-CYCLOPENTADITHIOPHENE AND NEW METHODS FOR SYNTHESISING THE SAME | DDT, NISCH, DBH | CA2 113/4885TSHR 784/4885CYP3A4 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.